BREAST NEOPLASMS

This early-phase trial tests a new treatment for people with a type of stomach cancer that has spread to the lining of the abdomen. The therapy uses the patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The main goals are to chec…

This study tests a new way of giving chemotherapy called adaptive therapy for people with advanced breast cancer that has gotten worse after standard treatments. The goal is to see if this approach can keep the cancer under control longer and with fewer side effects. About 192 pa…

This study tests whether a daily pill (Z-endoxifen) plus a monthly shot (goserelin) can slow or stop tumor growth in premenopausal women with ER+/HER2- breast cancer. About 87 participants will take the combination for up to 24 weeks before surgery. The main goal is to see if the…

This early-stage study tests an experimental pill called CID-078 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. About 220 adults with cancers like lung, breast…

This study looks at whether adjusting chemotherapy doses based on a patient's DPYD gene test can lower the risk of severe side effects. About 100 adults with certain cancers (like colorectal or breast) will get either a standard or a gene-guided lower dose. The goal is to see if …

This study tests a new handheld robotic tool, HandX, to help surgeons perform nipple-sparing mastectomy through a small side incision, reducing scarring and improving comfort. About 15 women with early breast cancer or high genetic risk will take part. Researchers will track surg…

This study tests whether adding the experimental drug BNT327 to standard chemotherapy helps people with a tough-to-treat type of advanced breast cancer (triple-negative) live longer without their cancer growing. About 558 participants who cannot receive current immunotherapy will…

This study tests whether adding a new drug (LY4064809) to standard hormone therapy and a CDK4/6 inhibitor can better control advanced HR+, HER2- breast cancer with a PIK3CA mutation. About 920 adults who have not had prior treatment for advanced disease will participate. The goal…

This study tests a medicine called disitamab vedotin in 100 adults with advanced HER2-positive breast cancer that has spread and is hard to treat. Participants receive the drug as an IV infusion every two weeks. The goal is to see if the drug can shrink tumors and to check its sa…

This study tests a new drug, patritumab deruxtecan, against standard chemotherapy or another drug for people with a common type of advanced breast cancer (HR+/HER2-). The goal is to see if the new drug helps people live longer or keeps the cancer from growing. About 1000 adults w…

This study offers ongoing access to the drug niraparib for people with ovarian or breast cancer who have already been taking it in a previous study and are still benefiting. The main goal is to monitor long-term safety and side effects. About 30 participants will continue treatme…

This study tests whether adding a targeted therapy called Sac-TMT to standard chemotherapy and immunotherapy (pembrolizumab) can eliminate more cancer before surgery in people with high-risk, early-stage triple-negative or hormone-receptor-low/HER2-negative breast cancer. About 2…

This study tests whether adding elacestrant to standard chemotherapy (capecitabine) can help people with advanced estrogen receptor-positive (ER+) breast cancer that no longer responds to CDK 4/6 inhibitors. About 297 participants will be randomly assigned to get either the combi…

This early-stage study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced breast, colorectal, prostate, or endometrial cancer that has spread. The goal is to find a safe dose and see if it s…

This study tests a combination of two drugs, elacestrant and abemaciclib, in people with a specific type of breast cancer (ER-positive, HER2-negative) that has spread to the brain. The goal is to see if the combination can shrink or control brain tumors. About 73 adults are being…

This study tests a new medicine called izalontamab brengitecan for people with advanced triple-negative breast cancer or ER-low breast cancer that cannot be treated with immunotherapy. The drug targets specific proteins on cancer cells to deliver a chemotherapy-like payload direc…

This study tests a new drug, MK-2870, alone or with another drug (pembrolizumab), against standard treatments for people with a common type of advanced breast cancer (HR+/HER2-). About 1,200 participants whose cancer has spread or cannot be removed will be randomly assigned to on…

This study is testing a new drug called patritumab deruxtecan in people with a type of advanced breast cancer (HER2-positive) that has spread or cannot be removed by surgery. The main goals are to see if the drug is safe and if it can shrink or eliminate tumors. About 81 particip…

This early-stage study tests a new drug called LY4337713 in people with advanced cancers (like pancreatic, breast, ovarian, or colorectal) that have high levels of a protein called FAP. The drug delivers radiation directly to cancer cells. The main goals are to check safety, find…

This observational study follows about 3,250 people with HR+/HER2- early breast cancer who are at high risk of the cancer coming back. Researchers are watching how well Kisqali (ribociclib) plus an aromatase inhibitor works in everyday medical practice, checking safety, how well …

This study tests whether tirzepatide, a weight-loss drug, can help eliminate tiny amounts of cancer left after standard treatment in 48 patients with obesity or overweight and a high-risk type of early breast cancer. The goal is to see if weight loss leads to metabolic changes th…

This study looks at whether a blood test (Signatera) can help decide when to start a targeted therapy (CDK4/6 inhibitor) in people with intermediate-risk HR+ HER2- breast cancer. About 725 participants will be monitored with regular blood draws; if the test detects cancer DNA, th…

This study tests a combination of two drugs—disitamab vedotin and tucatinib—for people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combo is safe and can shrink or control tumors. About 172 adults with these cancers who have a…

This study tests whether adding a new drug (patritumab deruxtecan) to standard chemotherapy and immunotherapy before surgery can eliminate more cancer cells in people with high-risk early-stage triple-negative or hormone-receptor-low breast cancer. About 372 participants will be …

This study is testing two new imaging agents that light up breast cancer cells on PET scans. Researchers want to see if these agents can find tumors and their spread more accurately than current methods. About 200 women with breast cancer or suspected breast cancer will receive t…

This study is gathering images from up to 800 women with suspicious breast findings to see if a new 3D automated ultrasound system (ATUSA) can accurately detect cancer. Participants will have their standard imaging and biopsy results compared with the ATUSA scans. The goal is to …

This study looks at whether adding a special type of mammogram (contrast-enhanced mammography) every two years to the usual yearly 3D mammogram can find breast cancer earlier in women who have already had breast cancer. About 1,500 women will take part. The goal is to improve det…

This study tests whether an augmented reality (AR) system can help surgeons remove breast cancer more completely during breast-conserving surgery. About 94 women with breast cancer will be randomly assigned to have surgery guided by either the AR tool or the standard ultrasound m…

This pilot study tests whether a newer PET tracer, 68Ga-FAPI-46, can find more cancer spots than the standard tracer (18F-FDG) in people with ER-positive breast cancer. About 20 women with advanced or recurrent breast cancer will receive both tracers to see which one detects more…

This study looks at whether an AI tool that collects family cancer history through WhatsApp can accurately predict a woman's genetic risk for breast cancer. Researchers will compare the AI's results with standard genetic tests in 800 women already identified as high-risk. If succ…

This study tests a decision aid for women aged 70 and older with early-stage, low-risk breast cancer. The tool helps them and their doctors discuss treatment options, aiming to reduce aggressive treatments like mastectomy or radiation when they may not be needed. About 400 partic…

This study looks at whether a program of exercise and personalized nutrition, started right after diagnosis and before treatment begins, can help women with breast cancer feel better and recover faster. Researchers will measure fitness, strength, and quality of life in 66 women. …

This study looks at whether a supervised exercise program with resistance training and relaxation can improve muscle mass and quality of life in women who have finished breast cancer treatment. About 66 participants will either join a therapist-led program at a facility or do exe…

This study compares two approaches for breast cancer patients who need a mastectomy and radiation. The experimental group gets radiation before surgery with immediate reconstruction, while the standard group gets radiation after surgery with delayed reconstruction. The goal is to…

This study tests whether a dexamethasone mouthwash can reduce mouth sores caused by the cancer drug datopotamab deruxtecan (Dato-DXd). About 60 adults with advanced HER2-negative breast cancer or non-small cell lung cancer will use the mouthwash four times a day for the first fiv…

This observational study tracks how the lymphatic system changes after radiotherapy in 40 women with breast cancer. Using a safe dye and special imaging, researchers hope to spot early signs of lymphedema (arm swelling) before it becomes a problem. Participants receive no experim…

This study is testing a mobile decision tool for breast cancer patients who have had surgery. 20 participants will use the tool on their phones and share their thoughts out loud. Researchers will measure how much patients learn about reconstruction options and gather feedback to …

This study aims to create a computer-based tool that predicts which cancer patients are at risk of heart damage from certain chemotherapy drugs. Researchers will follow 600 patients in France for one year, collecting data to train a machine learning model. The goal is to help doc…

This study takes small samples of breast cancer that has spread to the brain or other organs and grows them in the lab as mini-tumors (organoids). Researchers will test whether these mini-tumors can predict how well a patient's cancer responds to treatments like chemotherapy or r…

This study looks at genetic markers on breast cancer cells before and after chemotherapy. Researchers want to see how these markers change and whether they can help predict if the cancer will come back. The study involves 300 adults with stage II, III, or IV breast cancer who are…

This study looks at why some breast cancer patients get diarrhea from the drug Abemaciclib while others don't. Researchers will compare the gut bacteria of 60 women who have diarrhea with those who don't, using stool samples. The goal is to find if certain bacteria protect agains…

This study is testing whether adding new experimental drugs to standard chemotherapy before surgery can improve outcomes for people with breast cancer. It includes up to 5,000 participants with early-stage or locally advanced breast cancer. The goal is to use MRI scans and tissue…

This study looks at whether a protein called SGLT2 can help identify breast cancer patients at higher risk for heart damage from a common chemotherapy drug (anthracycline). Researchers will measure SGLT2 levels in blood and cells before and after treatment. The goal is to better …

This study follows 100 women with early-stage breast cancer for two years after surgery and other treatments. Researchers will measure changes in muscle mass and body fat to understand how the body recovers. The goal is to learn more about long-term health and quality of life aft…

This study is creating a registry of up to 1867 people with advanced or metastatic breast cancer that cannot be removed by surgery. Researchers will collect information on cancer subtypes, patient characteristics, and how the disease progresses over time. The goal is to better un…

This study follows 800 adults with advanced HER2-positive, low, or ultralow breast cancer who are receiving the drug trastuzumab deruxtecan as part of their normal care. Researchers will track how long patients stay on the drug before switching treatments and how their quality of…

This study enrolls 3,300 women in North Carolina with invasive breast cancer to understand why some groups have worse outcomes. Participants receive a program to improve communication with their doctors and self-advocacy. The goal is to see if this support can help reduce differe…

This study aims to learn why breast cancer risks and outcomes vary among different people. Researchers will collect blood, tissue samples, and survey data from 800 adults in South Florida. The goal is to find genetic and non-genetic factors that may explain these differences.

This study collects thousands of breast ultrasound images and has expert doctors label them. Then, different AI models are tested to see how accurately they can identify cancer compared to the experts. The goal is to build a standard way to evaluate AI for breast imaging, not to …

This study follows 3000 women with early-stage breast cancer to understand how treatments like surgery, chemo, and radiation affect their quality of life and cause side effects. Participants will fill out surveys and have heart, lung, and blood tests over time. The goal is to lea…

This study follows 30 women aged 18-70 who are having DIEP flap breast reconstruction after breast cancer surgery. Researchers will take blood samples before and after surgery to measure markers of inflammation and stress. The goal is to learn more about how the body heals and to…